Global Experts Unite in Special Journal Issue to Accelerate Cervical Cancer Elimination

Cervical cancer is positioned to become the first human cancer eliminated through coordinated global action, according to a new special issue of Cancer Biology & Medicine that brings together leading experts worldwide to examine progress, challenges and innovations in prevention, screening and treatment. The collection provides a timely resource for accelerating the World Health Organization's 2030 targets for cervical cancer elimination and advancing women's health equity globally, featuring contributions spanning policy frameworks, epidemiological insights, digital health tools and therapeutic vaccines.

Each year, more than 340,000 women die from cervical cancer, with the majority of deaths occurring in low- and middle-income countries. Despite being highly preventable through vaccination and early detection, the disease remains the fourth most common cancer among women globally. In 2020, the WHO launched the Global Strategy to Accelerate the Elimination of Cervical Cancer, setting ambitious "90-70-90" targets for vaccination, screening and treatment by 2030. However, vast inequities in health resources, infrastructure and implementation capacity threaten progress toward these goals.

The special issue, available at https://www.cancerbiomed.org/content/22/9, was guest-edited by Professor Youlin Qiao of the Chinese Academy of Medical Sciences & Peking Union Medical College and marks the 30th anniversary of the Fourth World Conference on Women and the 2025 World Women's Summit in Beijing. The issue highlights global disparities, China's contributions and the collective scientific and policy innovations needed to accelerate progress, reflecting the journal's mission to bridge cutting-edge oncology research with public health priorities in women's health.

Ten contributions span global perspectives, policy analysis, epidemiology, digital innovation, economic evaluation and novel therapeutics. Highlights include an editorial from the International Agency for Research on Cancer outlining global disparities and China's contributions, a perspective exploring how policy modeling can guide resource-sensitive elimination strategies in low- and middle-income countries, and an original article analyzing cervical cancer burden and trends in China from 2000 to 2020 compared with four Asia-Pacific countries.

Technological and clinical advances featured in the issue include the first international evaluation of a bilingual digital colposcopy education tool (iDECO), which significantly improves diagnostic accuracy, and the development of a therapeutic multi-epitope protein vaccine targeting HPV16 that demonstrates strong tumor regression in preclinical models. Additional research covers HPV vaccination willingness, innovative triage algorithms in rural China, intelligent digital platforms for population-based screening, and the economic impact of government-organized programs.

Professor Qiao emphasized that "cervical cancer is the only malignancy we can realistically eliminate through vaccination, screening and early treatment. This special issue demonstrates the collective knowledge and innovation needed to achieve that goal. By combining science, policy and equity, we can ensure that no woman is left behind in the global drive to eliminate cervical cancer." The timing aligns with renewed global attention to women's health at the 2025 World Women's Summit, providing evidence-based insights across epidemiology, technology, economics and therapeutics to inform international collaboration.

The elimination of cervical cancer represents not only a public health objective but also a milestone for gender equity and global health justice. As the world moves closer to this unprecedented achievement, the special issue serves as both a progress report and call to action, demonstrating that eliminating cervical cancer is possible within our lifetime but requires coordinated global cooperation. The journal Cancer Biology & Medicine is a peer-reviewed open-access publication sponsored by China Anti-cancer Association and Tianjin Medical University Cancer Institute & Hospital, with all full texts freely accessible worldwide at http://www.ncbi.nlm.nih.gov/pmc/journals/2000/.